Home
Live Updates
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC : comparemela.com
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
Related Keywords
Massachusetts ,
United States ,
Boston ,
Dana Farber Cancer Institute ,
America ,
Toni Choueiri ,
Nancy Kohlberg ,
Memorial Sloan Kettering Cancer Center ,
International Metastatic ,
Database Consortium ,
Professor Of Medicine At Harvard Medical School ,
Lank Center ,
Genitourinary Oncology At Dana Farber Cancer Institute ,
Genitourinary Oncology ,
Kidney Cancer Program ,
Harvard Cancer Center ,
Nancy Kohlberg Chair ,
Harvard Medical School ,
Western Europe ,
North America ,
comparemela.com © 2020. All Rights Reserved.